Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a chimeric IgG1 monoclonal antibody targeted against HER2/ERBB2. The original monoclonal antibody is derived from the parent antibody (Trastuzumab). Both antibodies bind efficiently to the same epitope of HER2 and mediate similar effects on cancer cells. However, in contrast to Trastuzumab, the Fc region of this monoclonal antibody is modified to increase the binding to CD16A and reduced binding to CD32B. Increased binding to CD16A leads to increased antibody-dependent cellular cytotoxicity (ADCC). The monoclonal antibody binds to the extracellular domain of HER2 expressed on tumor cells, inhibits tumor growth, and promotes ADCC. The original antibody received FDA approval to treat patients with metastatic HER2 cancer either alone or in combination with chemotherapy
Biovision | A2284 | Anti-HER2 (Margetuximab), Chimeric Antibody DataSheet
Antibody Target: HER2
Target Alternative Name: NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19; HER-2/neu, ERBB2, EC 2.7.10.1, Herstatin, P185erbB2, EC 2.7.10, MLN19
Tag Line: The biosimilar is a chimeric monoclonal antibody that targets HER2
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human HER2
Accession #: DB14967
Gene ID: 2064
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
